Prospective pilot study of Floseal® for the treatment of anterior epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT)

John M Lee, Vincent Wu, Marie E Faughnan, Andrea Lasso, Andrea Figol, Shaun J Kilty, John M Lee, Vincent Wu, Marie E Faughnan, Andrea Lasso, Andrea Figol, Shaun J Kilty

Abstract

Background: Epistaxis is the most common symptom of hereditary hemorrhagic telangiectasia (HHT), affecting more than 98% of adults with HHT, with significant impact on quality of life. Floseal® has been shown to be effective for the management of anterior epistaxis, but has yet to be thoroughly evaluated in this population. Our goal was to evaluate the efficacy of Floseal® for managing acute anterior epistaxis in patients with HHT.

Methods: A pilot prospective clinical trial was conducted at two tertiary referral centres, St. Michael's Hospital, Toronto, Canada and The Ottawa Hospital, Ottawa, Canada. All patients with HHT presenting with acute anterior epistaxis to the two study centres, who enrolled in the study, received Floseal® treatment. The primary outcome measures were achievement of hemostasis and changes in the Epistaxis Severity Score (ESS) between baseline and one-month follow up. Secondary outcome measure included clinical assessment of the nasal cavity.

Results: Seven patients were included in the final analysis. All patients underwent treatment of anterior epistaxis with Floseal® and achieved control of epistaxis within 15-min post-application. Application of Floseal® was well tolerated, with patients reporting a pain score of 3 ± 3.13 out of 10. There was no statistically significant difference noted in ESS scores pre-treatment and one-month follow up, 6.27 ± 2.42 vs. 4.50 ± 2.44, p = 0.179. There was a significant improvement clinically on exam of the nasal cavity between baseline and at one-month follow up, indicated by a decrease in the clinical assessment score, 17.29 ± 7.70 vs. 9.57 ± 7.81 (p = 0.0088).

Conclusions: Patients with HHT presenting with acute epistaxis were able to achieve hemostasis with one application of Floseal®, with the procedure being very well tolerated with minimal pain. Although there was no significant change in ESS scores, clinical assessment of the nasal cavity revealed significant improvement at one-month follow up post treatment with Floseal®.

Trial registration: This multi-centered prospective clinical trial was registered with ClinicalTrials.gov ( NCT02638012 ). Registered on December 22, 2015.

Keywords: Epistaxis; Floseal®; HHT; Hereditary hemorrhagic telangiectasia.

Conflict of interest statement

Dr. John M. Lee has been a speaker for Baxter, USA. No other actual or perceived conflicts of interest exists for any other authors.

References

    1. Chin CJ, Rotenberg BW, Witterick IJ. Epistaxis in hereditary hemorrhagic telangiectasia: an evidence based review of surgical management. J Otolaryngol Head Neck Surg. 2016;45(1):3. doi: 10.1186/s40463-016-0116-8.
    1. Faughnan ME, Palda VA, Garcia-Tsao G, Geisthof UW, McDonald J, Proctor DD, et al. International guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. J Med Genet. 2009;48:63–87.
    1. LaBranche J, Nahirniak S, Vethanayagam D. Common bleeding disorders affecting individuals with hereditary hemorrhagic telangiectasia. Clin Invest Med. 2016;39(1):1–6. doi: 10.25011/cim.v39i1.26324.
    1. Begbie ME, Wallace GMF, Shovlin CL. Hereditary heamorrhagic telangiectasia (Osler-weber-Rendu yndrome): a view from the 21st century. Postgrad Med J. 2003;79:18–24. doi: 10.1136/pmj.79.927.18.
    1. Aassar OS, Friedman CM, White RI., Jr The natural history of epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope. 1991;101(9):977–980. doi: 10.1288/00005537-199109000-00008.
    1. Zarrabeitia R, Fariñas-Álvarez C, Santibáñez M, Señaris B, Fontalba A, Botella LM, Parra JA. Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT) Health Qual Life Outcomes. 2017;15(1):19. doi: 10.1186/s12955-017-0586-z.
    1. Merlo CA, Yin LX, Hoag JB, Mitchell SE, Reh DD. The effects of epistaxis on health-related quality of life in patients with hereditary hemorrhagic telangiectasia. Int Forum Allergy Rhinol. 2014;4(11):921–925. doi: 10.1002/alr.21374.
    1. Grigg C, Anderson D, Earnshaw J. Diagnosis and treatment of hereditary hemorrhagic telangiectasia. Ochsner J. 2017;17(2):157–161.
    1. Beyea JA, Rotenberg BW. Comparison of purified plant polysaccharide (HemoStase) versus gelatin-thrombin matrix (Floseal®) in controlling bleeding during sinus surgery: a randomized controlled trial. Ann Otol Rhinol Laryngol. 2011;120(8):495–8.
    1. Oz MC, Rondinone JF, Shargill NS. Floseal® matrix: new generation topical hemostatic sealant. J Card Surg. 2003;18:486–493. doi: 10.1046/j.0886-0440.2003.00302.x.
    1. Murray S, Mendez A, Hopkins A, El-Hakim H, Jeffery CC, Côté DW. Management of persistent epistaxis using Floseal® hemostatic matrix vs. traditional nasal packing: a prospective randomized control trial. J Otolaryngol Head Neck Surg. 2018;47(1):3. doi: 10.1186/s40463-017-0248-5.
    1. Le A, Thavorn K, Lasso A, Kilty SJ. Economic evaluation of Floseal® compared to nasal packing for the management of anterior epistaxis. Laryngoscope. 2018;128(8):1778–1782. doi: 10.1002/lary.27081.
    1. Kilty SJ, Al-Hajry M, Al-Mutairi D, Bonaparte JP, Duval M, Hwang E, Tse D. Prospective clinical trial of gelatin-thrombin matrix as first line treatment of posterior epistaxis. Laryngoscope. 2014;124(1):38–42. doi: 10.1002/lary.24240.
    1. Hertzog MA. Considerations in determining sample size for pilot studies. Res Nurs Health. 2008;31(2):180–191. doi: 10.1002/nur.20247.
    1. Warner L, Halliday J, James K, de Carpentier J. Domiciliary Floseal® prevents admission for epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope. 2014;124(10):2238–2240. doi: 10.1002/lary.24701.
    1. Ujam A, Awad Z, Wong G, Tatla T, Farrell R. Safety trial of Floseal® haemostatic agent in head and neck surgery. Ann R Coll Surg Engl. 2012;94(5):336–339. doi: 10.1308/003588412X13171221590971.
    1. Vaiman M, Martinovich U, Eviatar E, Kessler A, Segal S. Fibrin glue in initial treatment of epistaxis in hereditary haemorrhagic telangiectasia (Rendu–Osler–Weber disease) Blood Coagul Fibrinolysis. 2004;15(4):359–363. doi: 10.1097/00001721-200406000-00012.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever